Brief: FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
07/11/2025 13:39
Nov 7 (Reuters) - Halozyme Therapeutics Inc HALO.O: FDA APPROVED DARZALEX FASPRO® FOR ADULT PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA Source text: ID:nPn1lHcTYa Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets